We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy.
- Authors
Tominaga, Naoomi; Hagiwara, Keitaro; Kosaka, Nobuyoshi; Honma, Kimi; Nakagama, Hitoshi; Ochiya, Takahiro
- Abstract
Background The tetraspanin CD63 is a highly N-glycosylated protein that is known to regulate cancer malignancy. However, the contribution of glycosylation of CD63 to cancer malignancy remains unclear. Previously, we reported that ribophorin II (RPN2), which is part of an Noligosaccharyle transferase complex, is responsible for drug resistance in breast cancer cells. In this study, we demonstrate that cancer malignancy associated with the glycosylation of CD63 is regulated by RPN2. Results Inhibition of RPN2 expression led to a reduction in CD63 glycosylation. In addition, the localization of CD63 was deregulated by knockdown of RPN2. Interestingly, multi-drug resistance (MDR1) localization was displaced from the cell surface in CD63-silenced cells. CD63 silencing reduced the chemoresistance and invasion ability of malignant breast cancer cells. Furthermore, the enrichment of CD63/MDR1-double positive cells was associated with lymph node metastasis. Taken together, these results indicated that high glycosylation of CD63 by RPN2 is implicated in clinical outcomes in breast cancer patients. Conclusions These findings describe a novel and important function of RPN2-mediated CD63 glycosylation, which regulates MDR1 localization and cancer malignancy, including drug resistance and invasion.
- Subjects
TETRASPANIN; GLYCOSYLATION; RIBOPHORINS; CANCER cells; GENE expression; DRUG resistance in cancer cells
- Publication
Molecular Cancer, 2014, Vol 13, Issue 1, p1
- ISSN
1476-4598
- Publication type
Article
- DOI
10.1186/1476-4598-13-134